Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1-Reference-Cited by-同舟云学术

Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1

Published:2016-04-07 Issue:14 Volume:127 Page:1803-1813
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Gu Shengqing¹²,Chan Wayne W.³⁴,Mohi Golam⁵,Rosenbaum Joel³,Sayad Azin²,Lu Zhibin²,Virtanen Carl²,Li Shaoguang⁶,Neel Benjamin G.¹²,Van Etten Richard A.³⁴

Affiliation:

1. Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada;

2. Princess Margaret Cancer Center, Toronto, ON, Canada;

3. Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA;

4. Program in Molecular and Cellular Physiology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA;

5. Cancer Biology Program, Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA; and

6. University of Massachusetts Medical School, Worcester, MA

Abstract

Key Points Scaffolding adaptor protein GAB2 is required for BCR-ABL1–evoked myeloid and lymphoid leukemogenesis. SHP2 and p85 binding to GAB2 activate distinct signaling pathways and are required differentially for myeloid and lymphoid leukemogenesis.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/14/1803/1392701/1803.pdf

Reference56 articles.

1. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.;Mahon;Lancet Oncol,2010

2. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.;Druker;N Engl J Med,2001

3. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.;Sawyers;Blood,2002

4. Molecular biology of bcr-abl1-positive chronic myeloid leukemia.;Quintás-Cardama;Blood,2009

5. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.;Hu;Proc Natl Acad Sci USA,2006

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The binding selectivity of the C-terminal SH3 domain of Grb2, but not its folding pathway, is dictated by its contiguous SH2 domain;Journal of Biological Chemistry;2024-04

2. Targeting the Grb2 cSH3 domain: Design, synthesis and biological evaluation of the first series of modulators;Bioorganic Chemistry;2023-09

3. In the Pipeline: Emerging Therapy for CML;Pathogenesis and Treatment of Leukemia;2023

4. Analysis of domain-specific function reveals significant plasticity in BCR-ABL signaling;2022-10-20

5. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo;Leukemia;2021-12-13